How would you approach adjuvant therapy for a stage IIIA malignant Brenner tumor of the ovary?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

Does the data for ENGOT-ov65/KEYNOTE-B96 (pembrolizumab + paclitaxel +/- bevacizumab) influence how you will incorporate IO therapy into platinum-resistant ovarian cancer?

When do you plan to add bevacizumab to pembrolizumab/paclitaxel (KEYNOTE-B96) in patients with PD-L1 positive platinum-resistant ovarian cancer?

For a patient with advanced serous fallopian tube carcinoma involving the uterus, cervix, and vagina who is now s/p interval debulking surgery, would you offer adjuvant vaginal brachytherapy if the upper vaginectomy margin was positive?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.